TG Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

TG Therapeutics

28/02/2024 14:49

* TG Therapeutics Inc  TGTX.OQ  reported a quarterly
adjusted loss
of 10 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -39 cents.  The mean expectation of
seven analysts for the quarter was for a loss of 10 cents per
share. Wall Street expected results to range from -17 cents
to -4 cents per share.
    * Revenue rose 54,863.8% to $43.97 million from a year ago;
analysts expected $40.06 million. 
    * TG Therapeutics Inc's reported EPS for the quarter was a
loss
of 10 cents​.
    * The company reported a quarterly loss of $14.42 million.
    * TG Therapeutics Inc shares had fallen by 18.6% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 9.9%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for TG Therapeutics
Inc is $39.00 
This summary was machine generated from LSEG data February 28 at
02:49 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.10          -0.10          Met
 Sep. 30 2023      0.12           0.73           Beat
 Jun. 30 2023      -0.25          -0.34          Missed
 Mar. 31 2023      -0.37          -0.28          Beat